Public-registry trials using ISB 1302 325 ng/kg-D1;425 ng/kg -D8 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer | Ichnos Sciences SA | Breast Cancer | PHASE1 / PHASE2 | 5 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
